Established in 2018, Chiheal Biomed is situated in the Gulou District of Nanjing. Founded collaboratively by well-known experts in the industry, we operate as a CXO company specializing in providing pharmaceutical R&D technical services.
Guided by a mission that places clinical needs at the forefront, prioritizes innovative R&D, and centers around customer requirements, Chiheal Biomed is dedicated to delivering superior and efficient services to the pharmaceutical industry and a wide-ranging clientele. Our comprehensive services include "enterprise development planning and market value management, product proposal evaluation and pipeline planning, pharmaceutical research, formulation of non-clinical research protocols and project management, clinical research, and regulatory affairs."
Chiheal Biomed, guided by the principle of "Innovation Drives Development," extends its commitment to global clients, offering opportunities for the transfer and collaborative development of impactful Fast-Follow First-in-Class (FIC) innovative drugs. We take pride in delivering a comprehensive, "one-stop" service for innovative drug development, encompassing drug design, synthesis, pharmaceutical development, and clinical research services. Our platforms are designed to cater to the diverse nee
We have a pipeline of novel, fast-follow PCCs (preclinical-candidate-compounds) for the therapies of metabolic and endocrine disorders.
We leverage a platform based on generic drug development and consistency evaluation services, highlighting our strengths in specialization and efficiency. Our expertise spans multiple dosage forms, including oral solid formulations, inhalation formulations, topical formulations, eye drops, and injections.
We have established robust technological platforms for fundamental and applied research in Traditional Chinese Medicine (TCM), encompassing theory, key technologies in innovative drugs, and critical technologies in the TCM industry.
We provide services including research project initiation, R&D strategy guidance, regulatory registration consultation, technical consulting, review of application documents, and mock inspections. To date, we have successfully completed dozens of technical service projects and guided multiple oral solid dosage forms through generic drug consistency evaluation studies.
Aikang Pharma focuses its primary operations on Phase I-IV clinical trials and Bioequivalence (BE) studies, specializing in drug clinical research CRO services and comprehensive support for IND, ANDA, and NDA registrations. Our commitment lies in delivering pharmaceutical companies specialized services in drug clinical CRO and regulatory submissions for the Chinese market, expediting the process of product market entry.
Based on our proprietary pharmaceutical R&D platform, we independently initiate and develop projects. Upon achieving phased R&D results, we engage in various collaboration models.
Steadily advancing internationalization is a key component of our long-term development strategy. We consistently emphasize efficient and groundbreaking R&D innovation, balancing independent development with open collaboration. By integrating global resources and strengthening international partnerships, we build on our foundation of internal driving growth to achieve broader progress.
Company address: Room N203, Building A5, No. 199 Mufu East Road, Gulou District, Nanjing City
Contact information:
Mr Min (Business Manager) +86 13913359344 njzh_mzj@chihealbio.com.cn
Mrs Li (Business Manager) +86 18115167072 njzh_ln@chihealbio.com.cn
